09:54 AM EDT, 09/24/2025 (MT Newswires) -- Akari Therapeutics ( AKTX ) said Wednesday that preclinical data for its PH1 antibody drug conjugate payload showed potential to suppress levels of the AR-V7 receptor that drives the progression of hormone refractory prostate cancer.

Akari said it plans to develop PH1 as the first antibody drug conjugate therapy for prostate cancer, either as a first-line combination therapy or a second-line therapy.

The company said current therapies have not proven effective against AR-V7 driven tumors, highlighting a significant unmet need for treatment options in patients who fail to respond to androgen receptor pathway inhibitors.

Shares of Akari Therapeutics ( AKTX ) were up 9.8% in recent trading Wednesday.

Price: 0.84, Change: +0.07, Percent Change: +9.80